We are live on ! Find out more
PDLI

PDL BioPharma, Inc.
PDLI

Delisted

PDLI was delisted on the 30th of December, 2020.

Back to rankings

213 hedge funds and large institutions have $700M invested in PDL BioPharma, Inc. in 2015 Q3 according to their latest regulatory filings, with 34 funds opening new positions, 73 increasing their positions, 69 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

118% more call options, than puts

Call options by funds: $3.29M | Put options by funds: $1.51M

36% more first-time investments, than exits

New positions opened: 34 | Existing positions closed: 25

4% more funds holding

Funds holding: 204 → 213 (+9)

6% more repeat investments, than reductions

Existing positions increased: 73 | Existing positions reduced: 69

26% less capital invested

Capital invested by funds: $947M → $700M (-$247M)

Holders
213
Holders Change
+9
Holders Change %
+4.41%
% of All Funds
5.93%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
34
Increased
73
Reduced
69
Closed
25
Calls
$3.29M
Puts
$1.51M
Net Calls
+$1.78M
Net Calls Change
-$3.82M

Top Buyers

Rank Fund Capital Flow
1
First Trust Advisors
First Trust Advisors
Illinois
+$22.2M
2
RFC
Russell Frank Company
Washington
+$6.21M
3
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
+$5.16M
4
AL
AJO LP
Pennsylvania
+$2.98M
5
OSAM
O'Shaughnessy Asset Management
Connecticut
+$2.66M

Top Sellers

Rank Fund Capital Flow
1
Bank of Montreal
Bank of Montreal
Ontario, Canada
-$16.2M
2
Renaissance Technologies
Renaissance Technologies
New York
-$14.5M
3
GAM
Gotham Asset Management
New York
-$12.5M
4
LCP
Lombardia Capital Partners
California
-$10.5M
5
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$6.47M

PDLI Hedge Fund Activity: Q3 2015 in Review

213 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in PDL BioPharma, Inc. (PDLI) for Q3 2015, worth a combined $700M — down 26% from $947M a quarter earlier.

Buyers outnumbered sellers: 34 funds opened new PDLI positions and 25 closed out — a net gain of 9 holders — while 73 added to existing stakes and 69 trimmed.

The largest buyer was First Trust Advisors, adding an estimated $22.2M. The largest seller was Bank of Montreal, cutting an estimated $16.2M.

  • 213 institutional investors held PDL BioPharma, Inc. (PDLI) as of Q3 2015, up from 204 in Q2 2015.
  • Funds reported $700M of PDL BioPharma, Inc. stock for Q3 2015, down 26% quarter-over-quarter.
  • 34 funds opened new PDL BioPharma, Inc. positions in Q3 2015 and 25 closed out, a net change of +9 holders.
  • The largest PDL BioPharma, Inc. buyer in Q3 2015 was First Trust Advisors, an estimated $22.2M added.
  • The largest PDL BioPharma, Inc. seller in Q3 2015 was Bank of Montreal, an estimated $16.2M sold.

Based on aggregated 13F filings for Q3 2015.